Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC).
Ashwin Gollerkeri
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Michael S. Gordon
Research Funding - Pfizer
John M. Burke
Consultant or Advisory Role - Dendreon; Genomic Health; Seattle Genetics; Spectrum Pharmaceuticals
Ralph Hauke
No relevant relationships to disclose
Jiri Tomasek
Honoraria - seminar presentation
Donald A. Richards
No relevant relationships to disclose
Christopher DiSimone
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Scott S. Tykodi
Research Funding - Pfizer
Amit R. Mehta
No relevant relationships to disclose
Charles Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Rachelle Perea
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Nicholas J. Vogelzang
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Honoraria - GlaxoSmithKline; Novartis; Pfizer